James Barder, the chief executive officer of Futura Medical PLC (AIM:FUM, OTC:FAMDF), said the group had a very good 2021, building its partner distribution network.
The US is of course the big market for the company and despite having had numerous enquiries from parties interested in partnering with it in the US, Futura has decided to defer holding meaningful discussions until after the regulatory dossier submission in the US for MED3000, its topical gel formulation for the treatment of erectile dysfunction. The submission is expected to be made by the end of September 2022.
“Then we’ll be focusing on that, looking to do a deal. It won’t happen this year but I hope it will happen in 2023, around about the time that we get – hopefully – US approval [to market MED300 in the US]. That will completely derisk it from a commercial perspective, and I think we’ll be able to get a better deal,” Barder told Proactive.